Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2014 Bi-annual assessment report

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/20485
• EU PAS number:
  EUPAS6305
• Study ID:
  20485
• Official title and acronym:
  Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2014 Bi-annual assessment report
• DARWIN EU® study:
  No
• Study countries:
  Germany

  Netherlands

  Sweden

  United Kingdom
• Study description:
  The objective of this study is to describe atomoxetine (Strattera) utilization patterns for patients treated in Germany, United Kingdom (UK), Sweden, and the Netherlands
• Study status:
  Finalised

Research institution and networks

Institutions

Real World Evidence Solutions, IMS Health

France

Study timelines

Date when funding contract was signed

Planned: 16/08/2013

Actual: 16/08/2013

Study start date

Planned: 01/01/2014

Actual: 01/01/2014

Data analysis start date

Planned: 01/01/2014

Actual: 01/01/2014

Date of final study report

Planned: 28/03/2014

Actual: 09/04/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Study protocol

Initial protocol

EU DUS PASS

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)